Alogliptin/Metformin bulk supplier for pharma manufacturers

Alogliptin/Metformin Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 12.5mg+500mg / 12.5mg+850mg / 12.5mg+1000mg

Reference Brands: Kazano (USA), Vipdomet (EU)

Category: Diabetes

Alogliptin/Metformin is an oral medication for type 2 diabetes mellitus. It combines alogliptin, a DPP-4 inhibitor, and metformin, a biguanide, to help control blood sugar levels. The combination improves insulin response and reduces liver glucose production. Taken twice daily with meals, it is used when diet, exercise, or single-drug therapy is insufficient.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Alogliptin/Metformin? List it or send an offer →

Product Description:

Alogliptin / Metformin Hydrochloride tablets are an oral antidiabetic combination used for the management of type 2 diabetes mellitus. This formulation combines alogliptin, a DPP-4 inhibitor that enhances incretin hormone activity to increase insulin release and decrease glucagon levels, with metformin, which reduces hepatic glucose production and improves insulin sensitivity. Together, they provide effective glycemic control by targeting multiple pathways involved in glucose regulation. These tablets are commonly prescribed when monotherapy is insufficient and are typically used alongside diet and exercise to achieve better long-term blood sugar management and reduce the risk of diabetes-related complications.

Alogliptin/Metformin — third party manufacturing & bulk supply

Alogliptin/Metformin is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Alogliptin/Metformin is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Alogliptin/Metformin listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Alogliptin/Metformin →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Alogliptin / Metformin tablets are used to improve blood sugar control in adults with type 2 diabetes mellitus. This combination is prescribed when diet, exercise, or single-drug therapy is not sufficient to maintain proper glycemic control.

These tablets are made from alogliptin benzoate and metformin hydrochloride. Alogliptin is a DPP-4 inhibitor that increases incretin hormones to regulate insulin secretion, while metformin decreases hepatic glucose production and improves insulin sensitivity.

Common trade names include Kazano (USA), Vipdomet (EU/UK), and various generic brands available in India, LATAM, and other emerging markets.

The original product is developed and marketed by Takeda Pharmaceuticals. It is also made by other manufacturers, including in India. We match each enquiry with licensed makers whose documents fit your market.

The complete generic name is alogliptin benzoate and metformin hydrochloride.

Brand names include Kazano, Vipdomet, and various region-specific generic brands.

These tablets are manufactured globally in countries such as the USA, UK, EU nations, India, and LATAM regions by both innovator and generic pharmaceutical companies.